Clinical Trial

A Real-world Study of Inetetamab for First-line Treatment of MBC

Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated August 8, 2023 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
This is a prospective, multicenter, real-world study aimed at evaluating the efficacy and safety of inetetamab+chemotherapy or inetetamab+pyrotinib+chemotherapy or inetetamab+pertuzumab+chemotherapy in the treatment of HER2 positive inoperable locally advanced or recurrent metastatic breast cancer. The research results will provide new targeted treatment strategies for HER2 positive breast cancer patients.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-08-04.
Trial Details
NCT Number NCT05980208
Lead Sponsor Hunan Cancer Hospital
Collaborators: Hunan Medical University General Hospital
Conditions Breast Cancer, Real-world Study
Enrollment 150 participants
Start Date 2023-09-01
Primary Completion 2025-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2023-08-08